Omeprazole (Synonyms: OMEP, OMP, OMZ) |
Catalog No.GC13166
One-Click Copy Product Info
|
Omeprazole is an inhibitor of gastric H+/K+ ATPase (PPI) with an IC50 value of 1.1μM for porcine ATPase. Omeprazole has competitive inhibitory effects on CYP2C19 activity with an inhibition constant (Ki) of 2 to 6μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 73590-58-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Omeprazole is an inhibitor of gastric H+/K+ ATPase (PPI) with an IC50 value of 1.1μM for porcine ATPase. Omeprazole has competitive inhibitory effects on CYP2C19 activity with an inhibition constant (Ki) of 2 to 6μM [1-2]. Omeprazole can inhibit the growth of Gram-positive and Gram-negative bacteria [3]. Omeprazole can be used to treat duodenal and gastric ulcers, gastroesophageal reflux disease, and erosive esophagitis [4].
In vitro, Omeprazole (0.1, 1, 2, and 4μg/ml; 3 and 12 days) treatment significantly reduced the expression of CTR, c-fos, NFATc1, and MMP-9 in osteoclasts and osteoblasts (RAW264.7 and MC3T3-E1), regardless of the Omeprazole concentration. With the increase in Omeprazole concentration, the expression of osteocalcin and the ratio of OPG/RANKL in osteoblasts increased [5]. Omeprazole (0-300μM; 7 days) disrupted the morphology and inhibited proliferation of HK2, HPC, and HEK293T cells in a concentration-dependent manner, but had little effect on NRK cells [6].
In vivo, Omeprazole (20mg/kg/day; 2 weeks; oral) treatment improved the movement of mice in a gastric and intestinal disease model induced by hydrochloric acid cysteamine and reduced anxiety behavior [4]. Omeprazole (100mg/kg/day; 1 week; i.p.) treatment increased the bacterial colonization and myeloperoxidase (MPO) activity in the stomach of mice with Helicobacter pylori infection, and increased the expression of anti-apoptotic Bcl-2 protein in the gastric mucosa [7].
References:
[1] Smolka, A.J., Goldenring, J.R., Gupta, S., et al. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000. BMC Gastroenterol. 4(4), 1-11 (2004).
[2] Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827.
[3] Jonkers D, Stobberingh E, Stockbrügger R. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996;37(1):145-150.
[4] Rethinavel H S, Selvaraj D B, Balakrishnan S J, et al. Omeprazole treatment manifests anxiolytic effects in a cysteamine hydrochloride induced mouse model of gastrointestinal disorder[J]. Heliyon, 2022, 8(6).
[5] Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883.
[6] Xiong Z, Lai Z, Li S, et al. Potential Kidney Risks Associated With Clinical Doses of Omeprazole: In Vivo and In Vitro Studies[J]. Clinical and Experimental Pharmacology and Physiology, 2025, 52(8): e70050.
[7] Maróstica M, Arçari D P, Bartchewsky Jr W, et al. Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori-infected mice[J]. Scandinavian journal of gastroenterology, 2007, 42(12): 1404-1412.
| Cell experiment [1]: | |
Cell lines | HK2, NRK, 293 T and HPC cells |
Preparation Method | The HK2 cell proliferation culture conditions consisted of 95% F12 + 5% fetal bovine serum (FBS) + penicillin/streptomycin and were maintained in an atmosphere of 95% air and 5% CO2. NRK, 293 T and HPC cells were cultured in 90% Dulbecco's modified Eagle medium (DMEM) + 10% FBS + penicillin/streptomycin. The cells were passaged every 3 days and cultured with Omeprazole in 96-well plates at 37°C. Following a 7-day incubation period, the culture medium was replaced with fresh medium and the CCK-8 reagent was added. After a 2h incubation, absorbance was measured at 450nm using a microplate reader. |
Reaction Conditions | 0-300μM; 7 days |
Applications | Omeprazole disrupted the morphology and inhibited the proliferation of HK2, HPC and HEK293T cells in a concentration-dependent manner, but had little effect on NRK cells. |
| Animal experiment [2]: | |
Animal models | BALB/c mice |
Preparation Method | Four to five months old experimental adult BALB/c mice (N = 24) were randomly divided into four groups namely, (1) control (C) group (N = 6), (2) cysteamine HCl (CystM) group (N = 6), (3) Omeprazole (OMP) group (N = 6) and (4) cysteamine HCl with Omeprazole (CystM + OMP) group (N = 6). The animals were maintained in the standard condition at a temperature of about 22–24°C in 12 hours of light and dark alternative cycles in the animal house, Bharathidasan University. Mice were provided with standard rodent feed and water of free access. The experimental animals in group 2 and 4 received intraperitoneal injection of 60mg of cysteamine HCl per Kg body weight for 3 alternative days. Five days later animals in groups 3 and 4 were given 20mg of Omeprazole per Kg body weight through drinking water. The animals in the control group were given normal drinking water. After two weeks of Omeprazole treatment, experimental mice in all groups were subjected to behavioural tests such as OFT, LDB and EPM for assessing the level of anxiety as described earlier. |
Dosage form | 20mg/kg/day; 2 weeks; oral |
Applications | Omeprazole treatment improved the locomotor activity of mice in the gastric and intestinal disease model induced by hydrosulfanide and reduced anxiety behaviors. |
References: | |
| Cas No. | 73590-58-6 | SDF | |
| Synonyms | OMEP, OMP, OMZ | ||
| Chemical Name | 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide | ||
| Canonical SMILES | CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC | ||
| Formula | C17H19N3O3S | M.Wt | 345.42 |
| Solubility | ≥ 17.271mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.895 mL | 14.4751 mL | 28.9503 mL |
| 5 mM | 579 μL | 2.895 mL | 5.7901 mL |
| 10 mM | 289.5 μL | 1.4475 mL | 2.895 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)